INTRODUCTION
Neuropilin-1 (NRP1) is a single-pass transmembrane receptor that is present in various tissues and cell types. First described as an orphan receptor with adhesion properties (1, 2) , it was later identified as a receptor for members of the class 3 semaphorin (Sema3) family and of the vascular endothelial growth factor (VEGF) family (1) (2) (3) (4) (5) (6) . NRP1 is involved in multiple physiological and pathological processes. Its overexpression or targeted deletion in mice is embryonically lethal and results in severe cardiovascular defects, abnormal yolk sac and central nervous system vascularization, and defective great vessel remodeling (4, 7, 8) .
The extracellular domain of NRP1 is composed of different subdomains, which mediate its ligand binding specificity (9, 10) . The transmembrane and the juxtamembrane domains are responsible for receptor dimerization, which is required for Sema3A and VEGF-A 165 signaling (11) . The short NRP1 cytoplasmic tail lacks catalytic activity and interacts with the postsynaptic density protein, Drosophila disc large tumor suppressor, and zonula occludens-1 protein (PDZ) domain of the cytoplasmic protein GIPC1 (also known as synectin) (12) . This interaction is essential for arteriogenesis because it directs the trafficking of endocytosed VEGF receptor 2 (VEGFR-2) into Rab5a-positive endosomes upon VEGF-A 165 stimulation (13) . Because of its lack of catalytic activity, NRP1 is thought to act mainly as a binding element that recruits coreceptors responsible for intracellular signal transduction. For example, VEGF-A 165 binding to NRP1 induces the PDZ-binding domain-dependent formation of a NRP1-VEGFR-2 complex, which enhances VEGFR-2 intracellular signaling (6, 14, 15) .
VEGF is a potent permeability factor (16) . Through binding to VEGFR-2, it triggers T cell-specific adaptor-mediated Src activation and focal adhesion kinase (FAK) phosphorylation (17) (18) (19) (20) (21) (22) . These events lead to VEcadherin internalization and, ultimately, to the loosening of adherens junctions with disruption of the endothelial barrier (23, 24) . VEGF-mediated transcellular permeability has also been reported and relies on vesiculovacuolar organelles (VVO), grape-like clusters of interconnected vesicles and vacuoles, which, upon stimulation, allow the passage of solutes and macromolecules (25) .
A mutant form of VEGF-A 165 that does not bind VEGFR-2 maintains its capacity to induce permeability, whereas VEGF-D binding and activation of VEGFR-2 is not sufficient to induce vascular leakage (26) . These data suggest that other receptors participate in VEGF-A 165 -induced leakage. Several studies point to a role of NRP1 in this context. Selective NRP1 overexpression in porcine aortic endothelial cells demonstrates that it is required for VEGF-A 165 -mediated permeability (27) . Accordingly, a neutralizing NRP1 antibody attenuates vascular leakage upon VEGF-A 165 overexpression in mouse lungs (27) . Furthermore, mice expressing a soluble form of NRP1 in the skin show reduced permeability through a mechanism that cannot be attributed solely to sequestration of VEGF-A 165 , supporting a role for NRP1 in vascular permeability independent of VEGF-A 165 (28) .
Another class of permeability-inducing NRP1 ligands is the C-end rule (CendR) peptide family (29) . The presence of a specific R-x-x-R motif at the C-terminal end of these peptides mediates NRP1 binding, followed by their rapid cell internalization and tissue penetration. CendR peptides induce the extravasation of associated cargo (such as nanoparticles) or coinjected drug into tissues, suggesting activation of a bulk transport system (30) . Endocytosis of CendR peptides is distinct from previously known endocytic pathways, requires NRP1 interaction with synectin, and is regulated by nutrient supply to cells and tissues (31) . However, the role of endocytosis in increased permeability and the mechanism through which CendR peptides exert their functions remain unclear.
Here, we identified the NRP1 cytoplasmic domain as essential for acute vascular hyperpermeability induced by different NRP1 ligands: a ligandblocking antibody against NRP1 and a CendR peptide. We showed that these ligands induced NRP1 accumulation at endothelial cell-cell contacts and triggered in vitro and in vivo permeability in a VEGFR-2-independent manner. RESULTS VEGF-A 165 and a NRP1 ligand-blocking antibody induce NRP1 accumulation at endothelial cell-cell contacts
We investigated the role of NRP1 in VEGF-A 165 -induced vascular permeability by first studying NRP1 distribution in human umbilical vein endothelial cells (HUVECs) upon VEGF-A 165 stimulation. NRP1, which was present in intracellular vesicles and dispersed at the plasma membrane (0 min) (Fig. 1A) , strongly accumulated at cell-cell contacts within 5 min of VEGF-A 165 stimulation (5 min) (Fig. 1A) . Over time, NRP1 was partially internalized (30 min) (Fig. 1A) . VEGF-A 165 induced a similar NRP1 intercellular accumulation in human dermal blood endothelial cells (HDBECs) ( fig. S1 , upper panel). VEGF-A 121 , which has weaker affinity for NRP1 than VEGF-A 165 but maintains high affinity for VEGFR-2 (32, 33), had no noticeable effect on NRP1 localization ( fig. S2, upper panel) .
To examine whether direct binding of VEGF-A 165 to NRP1 was responsible for NRP1 accumulation at cell-cell contacts, we incubated HUVECs with a polyclonal blocking antibody directed against VEGF-A 165 -NRP1 binding (anti-NRP1) before stimulation with VEGF-A 165 . Surprisingly, NRP1 accumulated at cell-cell contacts after incubation with anti-NRP1 in the presence or even the absence of VEGF-A 165 , suggesting that this process occurred independently of VEGF-A 165 (Fig. 1B, lower panel, white arrows) . The control immunoglobulin G (IgG) did not affect basal or VEGF-A 165 -mediated NRP1 localization, confirming the specificity of the antibodyinduced effect (Fig. 1B, upper panel) . In HUVECs stimulated with anti-NRP1 alone, NRP1 initially accumulated at cell-cell contacts (5 min) (Fig. 1C) and partially internalized over time (30 min) (Fig. 1C) . Hence, anti-NRP1 did not act as an antagonist of NRP1 intercellular accumulation but as an agonist. Similar results were observed in HDBECs ( fig. S1, middle panel) .
A tetrameric CendR peptide induces NRP1 accumulation at endothelial cell-cell contacts Because both VEGF-A 165 and anti-NRP1 induced NRP1 relocalization in endothelial monolayers, we hypothesized that other NRP1 ligands might have a similar effect. We used the prototypic CendR peptide RPARPAR, which, like VEGF-A 165 , binds to the NRP1 b1 binding pocket (34) .
Stimulation of HUVECs with monomeric RPARPAR did not affect NRP1 localization ( fig. S2 , lower panel). Because CendR peptides are more efficient at penetrating tissues in oligomeric form (29), we conjugated biotinylated RPARPAR to neutravidin (NA) to obtain a tetrameric peptide (NA-RPARPAR). NA-RPARPAR induced a strong and rapid NRP1 accumulation at cell-cell contacts, which persisted for longer periods compared to VEGF-A 165 and anti-NRP1 stimulation (Fig.  1D) . A similar relocalization was observed in HDBECs ( fig. S1 , lower panel). These results confirmed that NRP1 intercellular accumulation was not VEGF-A 165 -specific and suggested that ligand-induced receptor clustering was necessary to promote NRP1 relocalization. Sema3A primarily binds the NRP1 a1-a2 domains and can also bind the b1 domain through its basic C-terminal extremity (9, 10, (35) (36) (37) . At concentrations up to 250 ng/ml, it did not cause NRP1 accumulation at cell-cell contacts in HUVEC monolayers ( fig. S3) . Nevertheless, at 500 and 1000 ng/ml, Sema3A induced a faint and partial NRP1 relocalization after 30-and 5-min incubation, respectively ( fig. S3 ). These results suggest that a strong affinity binding to NRP1 b1 domain is required to trigger receptor relocalization. NRP2, another member of the NRP family, shares a strong sequence and structural homology with NRP1. It binds to VEGF family members as well as to CendR peptides (38, 39) . Staining for NRP2 in stimulated HUVEC monolayers revealed that VEGF-A 165 had no effect on NRP2 localization, whereas NA-RPARPAR induced NRP2 accumulation at cell-cell contacts, albeit to a lesser degree compared to NRP1 ( fig. S4 ). These results are in accordance with the lower binding affinity of VEGF-A 165 and CendR peptides for NRP2 compared to NRP1 (33, 39) .
NRP1 relocalization does not occur through an increase in NRP1 cell surface abundance
To elucidate whether an increase in NRP1 cell surface abundance was responsible for its accumulation at cell-cell contacts, we first determined global NRP1 abundance in HUVECs before and after stimulation with VEGF-A 165 , anti-NRP1, and NA-RPARPAR. Neither NRP1 mRNA nor NRP1 protein abundance was changed after a 5-min stimulation ( fig. S5,  A and B) . We next confirmed that the ligand-blocking antibody anti-NRP1 could not access intracellular NRP1 pools by directly staining nonpermeabilized HUVEC monolayers, indicating that it triggered NRP1 relocalization by directly engaging cell surface NRP1 ( fig. S5C ). We also considered whether ligand binding to surface NRP1 could induce the recruitment of cytoplasmic NRP1 to the plasma membrane, and performed flow cytometry analyses to determine NRP1 surface abundance on HUVECs before and after stimulation. Each of the three examined ligands induced a unique response ( fig. S5D ). VEGF-A 165 stimulation triggered an increase in NRP1 cell surface abundance at 2 and 5 min, followed by a decrease at 30 and 60 min, whereas anti-NRP1 and NA-RPARPAR initially induced no change or a decrease in NRP1 cell surface abundance, respectively ( fig. S5D ). This difference might be due to the specificity of VEGF-A 165 , which also binds VEGFR-2 on HUVECs. Thus, the results suggest that NRP1 relocalization at cell-cell contacts did not require an increase of NRP1 cell surface abundance. Accordingly, preincubation of HUVEC monolayers with nocodazole to block possible microtubule-mediated NRP1 transport to the membrane (40-42) had no effect on NRP1 relocalization ( fig. S5E) . Together, the data imply that NRP1 relocalizes laterally through the plasma membrane.
VEGF-A 165 , NA-RPARPAR, and anti-NRP1 induce endothelial leakage in vitro and in vivo
We further investigated NRP1 relocalization at cell-cell contacts by costaining HUVECs with VE-cadherin ( Fig. 2A) . Upon stimulation with VEGF-A 165 , NA-RPARPAR, or anti-NRP1, NRP1 was found in close proximity or colocalized (white arrows) with VE-cadherin ( Fig. 2A) . We hypothesized that the NRP1 that accumulated at endothelial junctions participated in vascular permeability, and we consequently studied the effect of NRP1 stimulation on fluorescein isothiocyanate (FITC)-dextran leakage through a HUVEC monolayer. After a 5-min stimulation, VEGF-A 165, NA-RPARPAR, and anti-NRP1 induced a significant increase of dye leakage through the endothelial monolayer compared to phosphate-buffered saline (PBS) (Fig. 2B) . A time course experiment in which fluorescence leakage was measured after 5-, 15-, and 30-min stimulation confirmed that the maximum leakage induced by the ligands compared to PBS occurred after 5 min ( fig. S6A ). Monomeric RPARPAR did not significantly affect endothelial leakage ( fig. S6B ), in line with its inability to induce NRP1 relocalization ( fig. S2 ).
We next performed Miles leakage assays to measure permeability in vivo. VEGF-A 165 and NA-RPARPAR significantly increased Evans Blue extravasation in the skin compared to PBS, as previously shown (Fig. 2C) (29, 43) . Furthermore, we showed that anti-NRP1 also significantly induced vascular leakage (Fig. 2C) . Together, our data correlate ligand-mediated NRP1 accumulation at cell-cell junctions in endothelial monolayers with induced in vitro and in vivo vascular leakage, supporting a role for NRP1 relocalization in vascular permeability.
NA-RPARPAR and anti-NRP1 act through a signaling pathway distinct from VEGF-A 165
Binding of VEGF-A 165 to NRP1 bridges VEGFR-2 and NRP1 and enhances VEGFR-2 signaling (14) . We therefore asked if NA-RPARPAR . Leakage of FITCdextran 70 kD from the upper to the lower well was measured by comparing fluorescence values at 520 nm (mean ± SEM; n = 9 independent experiments; the median from three to six replicates per independent experiment was used for statistical analyses; Friedman test followed by Dunn's multiple comparison post hoc test; *P < 0.05 and **P < 0.01). (C) Wild-type mice were systemically injected with Evans Blue and then with PBS, VEGF-A 165 , NA-RPARPAR, anti-NRP1 antibody, and their respective controls. The extravasated dye concentration was measured at 620 nm, and results were expressed as a ratio between the tested substance and its control (mean; n = 10 to 15 mice per treatment; Kruskal-Wallis test followed by Dunn's multiple comparison post hoc test; **P < 0.01 and ***P < 0.001).
and anti-NRP1 would similarly induce VEGFR-2 activation and if this activation was required for NRP1 intercellular accumulation and vascular leakage. Toward this end, we analyzed the phosphorylation status of VEGFR-2 upon stimulation with the three different ligands. Whereas VEGF-A 165 induced strong VEGFR-2 phosphorylation, neither NA-RPARPAR nor anti-NRP1 activated the receptor (Fig. 3A) . Moreover, the phosphorylation status of the VEGFR-2 downstream kinases Akt, p38, and extracellular signal-regulated kinase 1 and 2 (ERK1/2), which are involved in VEGF-A 165 -induced permeability (44, 45), did not increase in HUVECs stimulated with NA-RPARPAR or anti-NRP1 compared to unstimulated cells (Fig. 3B) . These results were confirmed in HDBEC monolayers (fig. S7, A and B) and demonstrated that NA-RPARPAR-and anti-NRP1-induced effects were not mediated by VEGFR-2 activation. VEGF-A 165 -induced destabilization of the endothelial barrier is mediated by Src and FAK activation (19, 20, 22) . We consequently quantified kinase phosphorylation after stimulation by the different ligands. VEGF-A 165 induced a small but significant increase in the phosphorylation of Accumulation of NRP1 at cell-cell contacts and subsequent vascular leakage are independent of the activation of the tyrosine kinase activity of VEGFR We next examined the consequences of inhibiting the tyrosine kinase activity of VEGFRs on NRP1 relocalization and vascular leakage. The small tyrosine kinase inhibitor PTK787/ZK222584 (PTK/ZK; vatalanib) targets VEGFR-1, VEGFR-2, and VEGFR-3 [median inhibitory concentration (IC 50 ) of 0.077, 0.037, and 0.27 mM, respectively] and, to a lesser extent, plateletderived growth factor receptor and c-kit (47) . We incubated cultured HUVEC monolayers with PTK/ZK before stimulation with the different ligands. As expected, PTK/ZK inhibited VEGF-A 165 -induced VEGFR-2 phosphorylation (Fig. 4A) . However, NRP1 accumulation at cell-cell contacts induced by VEGF-A 165 , anti-NRP1, and NA-RPARPAR was not affected by PTK/ ZK treatment, showing that this process did not require VEGFR-2 activation (Fig. 4B) . Furthermore, knockdown of VEGFR-2 in HUVECs (Fig. 4C) did not affect NRP1 relocalization at cell-cell contacts (Fig. 4D ). These data demonstrated that VEGFR-2 was not required for VEGF-A 165 -, NA-RPARPAR-, or anti-NRP1-induced NRP1 relocalization to the endothelial junctions.
For in vivo analysis, we performed Miles assay experiments after systemic circulation of PTK/ZK. The kinase inhibitor did not significantly affect VEGF-A 165 -, NA-RPARPAR-, or anti-NRP1-induced vascular leakage, showing that these ligands induced permeability independently of VEGFR activation (Fig. 4, E to G ). Yet, PTK/ZK significantly inhibited VEGF-A 121 -induced leakage (Fig. 4H) , demonstrating the efficiency of the inhibitor at the concentration used and suggesting that this VEGF-A isoform required VEGFR activation to induce permeability. ). These mice are viable and fertile, with no overt developmental defects, suggesting that the extracellular domain mediates NRP1 functions during angiogenesis (48) . We observed a decrease in the VEGF-A 165 -induced leakage in NRP1cyto −/− mice compared to wild-type mice. However, the reduction was not significant, suggesting that the NRP1 cytoplasmic domain could participate in VEGF-A 165 -induced vascular leakage despite not being necessary (Fig. 5C ). On the other hand, vascular leakage was significantly decreased in NRP1cyto −/− mice compared to their wild-type littermates upon intradermal injection of either NA-RPARPAR or anti-NRP1, establishing that these non-VEGFR-2 binding NRP1 ligands induced vascular extravasation through the NRP1 cytoplasmic domain (Fig. 5, D and E) .
DISCUSSION
Here, we have identified direct ligand binding to NRP1 as a VEGFR-2-independent mechanism to induce vascular permeability in vitro and in vivo. Three different NRP1 ligands induced its accumulation at endothelial cell-cell contacts and enhanced solute permeability in a process that required the NRP1 cytoplasmic domain. Upon stimulation with VEGF-A 165 , anti-NRP1, and NA-RPARPAR, NRP1 rapidly accumulated at intercellular contacts of HUVEC or HDBEC monolayers, colocalized, or was in close proximity with VE-cadherin. This fast NRP1 concentration at endothelial junctions corresponds with a role of the receptor in acute hyperpermeability and could constitute the first step in junction opening or VVO formation. NRP1 relocalization upon ligand stimulation did not require an increase of NRP1 surface abundance and was not affected by inhibition of microtubule transport, suggesting that the receptor relocalized laterally across the plasma membrane to accumulate at intercellular junctions. Moreover, the data suggest that ligands that induce NRP1 oligomerization trigger its relocalization. NRP1 dimerizes through its juxtamembrane and transmembrane domains (9-11), and a peptide mimicking its transmembrane domain successfully inhibits VEGF-A 165 -and Sema3A-induced NRP1-mediated effects (11, 49) . The findings showing that monomeric RPARPAR did not affect NRP1 localization patterns and did not increase FITC-dextran leakage through HUVEC monolayers, together with a previous study demonstrating the increased NA-RPARPAR efficiency in vivo compared to RPARPAR (29) , support the concept that NRP1 multimerization is also required for cellcell contact accumulation and permeability induction.
VEGF-A 165 and NA-RPARPAR share the same binding site within the NRP1 b1 binding pocket (34, 37) . However, NRP1 binding to the b1 domain appears not to be sufficient to induce NRP1 cell-cell contact accumulation. VEGF-A 121 , which binds to b1 but lacks exon 7 present in other VEGF-A isoforms, did not induce NRP1 relocalization. Likewise, VEGF-A 121 -induced leakage was inhibited by PTK/ZK in the Miles assay, suggesting that this VEGF-A isoform acts primarily through the tyrosine kinase activity of VEGFRs to induce permeability. Sema3A is another vascular permeability-inducing factor that requires NRP1 for inducing leakage (46) . NRP1 a1 and a2 domains constitute the Sema3 primary binding sites, and whether Sema3 can compete with VEGF-A 165 for binding to the b1 domain is still under debate (50) (51) (52) (53) . In our hands, Sema3A only triggered a weak NRP1 relocalization at cell-cell contacts when used at high concentrations and thus probably induces vascular leakage through a different mechanism than VEGF-A 165 , NA-RPARPAR, and anti-NRP1. These data support the notion that not all NRP1 ligands trigger permeability through the same mechanism, which could reflect different physiological settings.
Unlike VEGF-A 165 and NA-RPARPAR, which bind to a specific site in NRP1, anti-NRP1 is a polyclonal antibody generated with an antigen covering a large portion of the receptor. Similar to VEGF-A 165 and NA-RPARPAR, it induced NRP1 accumulation at endothelial cell-cell contacts in vitro and vascular leakage in vivo. Strikingly, the same antibody has been previously used to inhibit CendR peptide-induced vascular leakage by antibody administration 30 min before Evans Blue injection (29) . In vivo, leakage induced by a single exposure of permeability-inducing agent begins within a minute and lasts for maximally 30 min (54) . Therefore, in the aforementioned work, the antibody permeability-inducing effects might have ended by the time the dye was injected. Another study used a ligand-blocking anti-NRP1 antibody to inhibit leakage in vitro and in vivo in a lung wet-dry weight model (27) . This antibody was produced with an uncharacterized antigen and might therefore bind to different site(s) than the antibody used in the present work. Moreover, the organ studied (lung compared to skin), the route (intraperitoneal compared to intradermal) and the frequency (multiple doses compared to single dose) of administration, the quantities used, and the length of treatment before stimulation were significantly different between these and our study, and the effects observed can therefore not be formally compared.
NRP1 has a closely related family member, NRP2. NRP1 and NRP2 share common ligands, among them VEGF-A 165 and CendR peptides (38, 39) . However, HUVEC stimulation with VEGF-A 165 had no effect on NRP2 localization, whereas NA-RPARPAR-induced NRP2 accumulation at the cell-cell contacts was weaker than the one observed with NRP1. These data are in accordance with VEGF-A 165 having lower affinity for NRP2 [dissociation constant (K d ) = 150 nM compared to 3 nM for NRP1] (33) and with the lower binding efficacy of phage-bound CendR peptides toward NRP2 compared to NRP1 (39) . Nevertheless, our data unambiguously demonstrate that NRP2 is also able to relocalize upon stimulation. NRP1 and NRP2 exhibit a differential distribution pattern, and NRP2 predominates in lymphatic vessels in particular (55) . VEGF-C is a high-affinity NRP2 ligand and a potent permeability factor involved in lymphangiogenesis (56, 57) . Similar to NRP1, NRP2 could therefore participate in vascular extravasation upon VEGF-C stimulation.
As a ligand for VEGF-A 165 , NRP1 is generally viewed as an enhancer of VEGFR-2-induced signaling (14) . However, we found that neither NA-RPARPAR nor anti-NRP1 triggered VEGFR-2 phosphorylation. Furthermore, VEGFR-2 knockdown did not affect NRP1 relocalization in HUVEC monolayers, and the multikinase inhibitor PTK/ZK similarly did not prevent NRP1 accumulation at cell-cell contacts, showing that VEGFR-2 was not required for this process. Moreover, vascular leakage induced by these ligands was not inhibited by PTK/ZK, further demonstrating that VEGFR-2 inhibition does not affect VEGF-A 165 -, NA-RPARPAR-, and anti-NRP1-induced vascular leakage. Using mice lacking the NRP1 cytoplasmic domain, we demonstrated the direct involvement of this domain in NA-RPARPAR-and anti-NRP1-induced permeability. Hence, both ligands induce vascular leakage in a VEGFR-2-independent manner through NRP1 cytoplasmic domain. These data are in line with previous publications showing a direct role for NRP1 in endothelial cell migration, survival, or permeability independently of VEGFR-2 (27, 58, 59) . They furthermore agree with the observation that CendR peptides require NRP1 cytoplasmic domain to induce internalization (31). However, VEGF-A 165 -mediated permeability was not significantly inhibited in NRP1cyto −/− mice. VEGF-A 165 is therefore able to compensate for the loss of NRP1 cytoplasmic domain, presumably through VEGFR-2. Reciprocally, PTK/ZK did not significantly decrease VEGF-A 165 -mediated permeability, showing that VEGF-A 165 can circumvent VEGF receptor inhibition. VEGF-A 165 therefore seems capable of inducing vascular leakage through both VEGFR-2 and NRP1, whereas NA-RPARPAR and anti-NRP1 only act through NRP1 (Fig. 5F ). This duality could account for the high variability observed in response to VEGF-A 165 in the Miles assay.
Whether VEGFR-2 and NRP1 act as a complex as shown previously remains to be determined.
The downstream events linking NRP1 cytoplasmic domain and vascular leakage are still unclear. NA-RPARPAR and anti-NRP1 did not activate the VEGFR-2 downstream kinases Akt, p38, and ERK1/2. A moderate and transient activation of Src upon NA-RPARPAR and anti-NRP1 stimulation was observed, suggesting that NRP1 activation could lead to Src-mediated endothelial destabilization and paracellular permeability independently of VEGFR-2 (24) . However, in vivo inhibition of Src did not prevent NA-RPARPAR-and anti-NRP1-induced vascular leakage. Moreover, FAK was not significantly activated after anti-NRP1 or NA-RPARPAR binding (20, 22) . The involvement of FAK/Src kinases in NRP1-mediated permeability therefore seems accessory. A recent study has demonstrated the importance of the NRP1-synectin interaction in CendR peptide-mediated endocytosis (31) , and synectin could similarly be involved in CendR peptide-mediated permeability. Moreover, the authors of that study reported the formation of engulfment structures in cancer cells that structurally resemble macropinocytotic vesicles. They proposed that these structures represent the first step in the formation of VVO, which would induce transcellular permeability (25) . It is therefore tempting to hypothesize that vascular leakage induced by NRP1 ligand binding could result from a transcellular mechanism. A better comprehension of the physiological and/or pathological context in which NRP1-mediated permeability takes place will help identify the route mediating leakage and could offer new perspectives in the treatment of acute or chronic hyperpermeability. , mouse monoclonal anti-Src, and rabbit monoclonal anti-phospho-FAK Tyr 397 were purchased from Cell Signaling Technology. Rabbit polyclonal anti-ERK1/2, rabbit polyclonal anti-FAK, goat polyclonal anti-NRP1, goat polyclonal anti-actin, and mouse monoclonal anti-GAPDH were from Santa Cruz Biotechnology. The mouse monoclonal anti-phosphotyrosine was from Millipore, and the mouse monoclonal anti-tubulin was from Sigma. For immunoprecipitation, the mouse monoclonal anti-VEGFR-2 was from ReliaTech.
MATERIALS AND METHODS

Antibodies and reagents
The ligand-blocking sheep anti-human NRP1 and goat anti-rat NRP1 antibodies were purchased from R&D Systems. Sheep and goat IgG antibodies (Dianova) were used as controls. The recombinant purified proteins mouse VEGF-A 120, mouse VEGF-A 164 , and human Sema3A were purchased from R&D Systems, and human VEGF-A 165 and human VEGF-A 121 were purchased from ReliaTech. Biotin-RPARPAR was synthesized by Peptide Specialty Laboratories, and tetrameric RPARPAR was obtained by conjugation with neutravidin (Pierce) as described previously (39) . The inhibitor PTK/ZK was purchased from Cell Signaling Technology, SKI-606 from Abcam, and nocodazole from Sigma.
Cell culture
HUVECs and HDBECs were purchased from PromoCell. HUVECs were cultured in Endopan 3 medium completed with the corresponding supplements (PAN Biotech), and HDBECs were cultured in Endothelial Cell Growth Medium MV2 completed with the corresponding supplement mix (PromoCell). Cells were used between passages 1 and 7 and cultured at 37°C with 5% CO 2 .
Cell transfection
Adenoviral constructs containing the complementary DNA (cDNA) for GFP, NRP1, and NRP1DC were generated with the Gateway System (Life Technologies) according to the manufacturer's instructions. HUVECs were transfected with 100 infectious units per cell 1 day before stimulation. For gene silencing experiments, HUVECs were transfected with 100 nM KDR siRNA (s7822 and s7823) or noncoding siRNA (Life Technologies) using 6 ml of Oligofectamine in Opti-MEM + GlutaMAX-I (Life Technologies). Validation of VEGFR-2 down-regulation by qRT-PCR analysis and functional experiments was performed 48 hours after transfection.
Cell stimulation and immunostaining
HUVECs were grown on 0.2% gelatin-coated coverslips (Thermo Scientific) until they formed a tight monolayer. After starvation with Endopan 3 without supplement for 5 to 6 hours, they were stimulated with VEGF-A 165 (50 ng/ml), NA-RPARPAR (peptide concentration, 1 mM), anti-NRP1 (3 mg/ml), or otherwise specified ligand. Cells were fixed and permeabilized with ice-cold methanol/acetone (50:50), blocked with 3% PBS/bovine serum albumin, and stained with primary antibodies at 4°C overnight. The appropriate secondary antibodies were incubated for 1 hour at room temperature. Nuclei were counterstained with Hoechst. The coverslips were mounted in Fluoromount-G mounting medium (eBioscience). Stainings were acquired on a motorized inverted Observer.Z1 (Zeiss) or a Zeiss LSM 710 confocal microscope. At least three microscopic fields were analyzed per monolayer. With an average of 20 cells per microscopic field of view, at least 150 cells were analyzed per experiment.
To inhibit VEGF-A 165 -NRP1 binding, ligand-blocking anti-NRP1 or its control sheep IgG was added to the starved monolayers at 4°C for 30 min before stimulation with VEGF-A 165 . PTK/ZK (100 nM) and nocodazole (20 mM) or the corresponding DMSO controls were added at 37°C for 30 min before stimulation.
Flow cytometry
NRP1 surface expression in HUVECs before and after stimulation was analyzed by flow cytometry. Single-cell suspensions were incubated with conjugated mouse anti-NRP1 or with the corresponding isotype control in basal medium containing 1% fetal calf serum for 30 min on ice. Sample acquisition was performed with a BD FACSCanto II flow cytometer, and subsequent analysis was done using FlowJo software.
In vitro permeability assay
HUVECs were grown on 0.4-mm fibronectin-coated (R&D Systems) Transwell filters (Coaster Transwell, Corning Inc.). After 48 hours, cells were starved with Endopan 3 without supplement for 5 to 6 hours. The medium in the upper well was then replaced by FITC-dextran 70 kD (0.5 mg/ml in PB; Sigma). Cells were stimulated in the lower well with PBS containing VEGF-A 165 (50 ng/ml), NA-RPARPAR (peptide concentration, 1 mM), RPARPAR (1 mM), or anti-NRP1 (3 mg/ml). The fluorescence in the lower well was read at 520 nm.
Immunoprecipitation and Western blots
HUVECs were grown on 0.2% gelatin-coated dishes until they formed a tight monolayer. After starvation with Endopan 3 without supplement, cells were stimulated with VEGF-A 165 (50 ng/ml), NA-RPARPAR (peptide concentration, 1 mM), or anti-NRP1 (3 mg/ml). Cells were washed with icecold PBS containing 1 mM orthovanadate and lysed in a tris-NaCl buffer (25 mM/150 mM) containing 5 mM EDTA, 1 % NP-40, 100 mM NaF, and 10 mM Na 4 P 2 O 7 in the presence of 1 mM orthovanadate and protease inhibitor mix G (SERVA Electrophoresis). For immunoprecipitation, cell lysates were incubated overnight with 1 mg of anti-VEGFR-2 and protein G-Sepharose (GE Healthcare). The Sepharose beads were washed, and the samples were boiled in sample buffer [250 mM tris-HCl (pH 6.8), 10% SDS, 0.5% bromophenol blue, 50% glycerin, supplemented with 10% b-mercaptoethanol]. Samples were subjected to 8% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), blotted onto a MeOH-activated polyvinylidene difluoride (PVDF) membrane, and probed with antibodies directed against VEGFR-2 and phosphotyrosine. To assess the phosphorylation of ERK1/2, Akt, p38, Src, and FAK, total protein lysates were heated to 95°C in sample buffer, subjected to 10% SDS-PAGE, and blotted onto a PVDF membrane probed with the desired antibodies. Western blot analysis was performed using horseradish peroxidase-conjugated secondary antibodies (DAKO), and bound antibody was visualized using enhanced chemiluminescence (Pierce). To reprobe blots, membranes were stripped in a stripping solution (Millipore) for 7 to 10 min and reprobed with the desired antibodies. When indicated, the resultant intensities were quantified using Fiji Is Just ImageJ software.
qRT-PCR
RNA of HUVECs was isolated with RNeasy Mini Kit (Qiagen). cDNA was synthesized with QuantiTect Reverse Transcription Kit (Qiagen). Subsequent qRT-PCR was performed with TaqMan Fast Advanced Mastermix (Life Technologies) and the desired TaqMan probes (GAPDH: Hs02758991_g1; ACTB: Hs01060665_g1; KDR: Hs00911700_m1; NRP1: Hs00826128_m1; Life Technologies) with a Roche LightCycler 480.
Miles assay
Evans Blue (100 ml; 1% in sterile saline; Sigma-Aldrich) was systemically injected in the lateral tail vein of C57BL/6 mice, wild type or knockout for the NRP1 cytoplasmic domain (NRP1cyto −/− ) (40). After 15-min circulation, 20 ml of ligand-containing solution and its control counterpart were injected each in one footpad of the mouse, which allowed having an internal control for each mouse [PBS compared to NaCl, VEGF-A 164 or VEGF-A 120 (50 ng) compared to 0.9% NaCl, anti-NRP1 antibody (5 mg) compared to goat IgG, and NA-RPARPAR (peptide concentration, 30 mM) compared to neutravidin]. Alternatively, the ligand-containing solution was injected intradermally in the abdomen region (Fig. 5E ). After 15 min, the skin containing the extravasated dye was excised with a 4-mm punch (Stiefel). Evans Blue was extracted by incubation in formamide at 55°C overnight and quantified by spectrometry at 620 nm (Multiskan EX, Thermo Scientific). Results are expressed as a ratio between the ligand-induced absorbance (in one foot) and its corresponding control-induced absorbance (in the other foot of the same mouse). When needed, PTK/ZK (10 mg/kg), SKI-606 (5 mg/kg), or the corresponding DMSO controls were injected intraperitoneally 30 min before Evans Blue injection. Animals were handled in accordance with the guidelines of the Regierungspräsidium Karlsruhe, Germany (permit no. G65-15).
Statistical analysis
Data were analyzed with GraphPad Prism (GraphPad Software Inc.). The statistical tests applied are indicated in the figure legend for each experiment.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/9/425/ra42/DC1 Fig. S1 . VEGF-A 165 , the ligand-blocking anti-NRP1 antibody, and NA-RPARPAR induce NRP1 accumulation at cell-cell contacts in HDBECs. Fig. S4 . NRP2 accumulates at cell-cell contacts upon stimulation with NA-RPARPAR, but not with VEGF-A 165 . Fig. S5 . NRP1 relocalizes at cell-cell contacts laterally through the plasma membrane. Fig. S6 . Maximum endothelial leakage is observed after 5 min, and monomeric RPARPAR does not induce endothelial leakage. Fig. S7 . NA-RPARPAR and anti-NRP1 do not activate VEGFR-2, Akt, ERK1/2, p38, and FAK in HDBECs. Fig. S8 . The Src inhibitor SKI-606 does not inhibit NA-RPARPAR-and anti-NRP1-induced vascular leakage.
